The authors previously reported ornithine cytotoxicity in ornithine-␦-aminotransferase (OAT)-deficient human retinal pigment epithelial (RPE) cells as an in vitro model of gyrate atrophy of the choroid and retina (GA). Given that RPE cells are severely damaged by arginine combined with ornithine, they investigated the role of arginine metabolism using that in vitro model. METHODS. Human telomerase reverse transcriptase (hTERT)-RPE cells were incubated with ornithine or other agents in the presence of 5-fluoromethylornithine (5-FMO), an OAT-specific inhibitor. mRNA expression was determined by quantitative real-time polymerase chain reaction, and the concentration of nitric oxide (NO) was quantified using a Griess assay. Furthermore, cytotoxicity was examined by morphologic observations and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assays, with the effect of arginase II examined using short interfering (si) RNA for arginase II and
G yrate atrophy of the choroid and retina (GA) is a rare autosomal recessive disease characterized by progressive chorioretinal degeneration that leads to blindness. The pathophysiology of GA is caused by a deficiency of the mitochondrial matrix enzyme ornithine-␦-amino transferase (OAT), which converts ornithine to glutamic-␥-semialdehyde. 1, 2 As for biochemical abnormalities associated with this disorder, the plasma ornithine concentration in GA patients is 10-to 15-fold greater than normal, which leads to hyperornithinemia and ornithinuria. 3 Ornithine is produced entirely from arginase; thus, an arginine-restricted diet consumed by GA patients causes a progressive reduction in plasma ornithine to a normal level, along with the disappearance of ornithinuria. 4 Chronic reduction of ornithine levels in plasma with an arginine-restricted diet has been reported to slow the progression of chorioretinal degeneration in GA patients 5, 6 and OAT-deficient mice. 7 The retinal pigment epithelium is a monolayer of cells situated between the neuro-retina and choroid and is the primary site of insult in GA, 2 whereas high OAT activity has been documented in retinal pigment epithelia. 8, 9 We recently established an in vitro model of GA using 5-fluoromethylornithine (5-FMO), a specific irreversible inhibitor of OAT, because inactivation of OAT in human retinal pigment epithelial (RPE) cells by 5-FMO makes them susceptible to ornithine, leading to cell death. 10 Ornithine is transported primarily by cationic amino acid transporter (CAT)-1 in the human RPE cell line hTERT-RPE, 11 whereas the gene expression of CAT-1 is induced by spermine, one of the metabolites of ornithine by ornithine decarboxylase (ODC), and exhibits ornithine cytotoxicity. 12 CAT-1 can transport arginine as well as ornithine, 13, 14 and hTERT-RPE cells are more severely damaged when arginine is combined with ornithine. 15 Thus, arginine and its metabolites are thought to be involved in the cytotoxicity of RPE cells in addition to the accumulation of ornithine.
Arginine is one of the most versatile amino acids because of its multiple metabolic pathways, and it serves as a precursor for the synthesis of protein, nitric oxide (NO), creatine, polyamines, agmatine, urea, and amino acids that are interconvertible with proline and glutamate. 16 -18 NO plays important roles in many diverse processes, including vasodilation, immune responses, neurotransmission, and adhesion of platelets and leukocytes, 16 and NO synthase (NOS) catalyzes the hydrolysis of arginine to NO and citrulline. There are three isoforms of NOS, neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial NOS (eNOS). Only iNOS expression is strongly regulated by various stimuli; nNOS and eNOS are expressed constitutively. RPE cells have been shown to produce NO through iNOS in response to several cytokines. 19 -21 On the other hand, arginine is hydrolyzed by arginase into urea and ornithine, the latter of which can serve as a precursor of polyamine, proline, and glutamate. Two forms of arginase, known as arginase I and arginase II, are localized in the cytoplasm and mitochondria, respectively, and are encoded by different genes. 18 Although arginase I is highly expressed in the liver as a component of the urea cycle, arginase II has been found at lower levels in the kidneys, brain, small intestines, mammary glands, and macrophages, with little or no expression in the liver. Furthermore, arginase II is expressed in RPE cells colocalized with OAT, whereas arginase I is not. 22 In the present study, we examined the role of the arginine metabolite pathway components NOS and arginase using our previously established in vitro model of GA. We found that NO was increased by ornithine in 5-FMO-treated hTERT-RPE cells and that it also induced cytotoxicity and transcriptional activation of arginase II and CAT-1 in hTERT-RPE cells.
MATERIALS AND METHODS

Cell Cultures
The human RPE cell line hTERT-RPE, 23 previously established by gene transfer of human telomerase reverse transcriptase cDNA, was kindly provided by Donald J. Zack (Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD). hTERT-RPE cells were maintained in Dulbecco's modified Eagle's (DME)/Ham F-12 medium (1:1; Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 g/mL streptomycin in 5% CO 2 at 37°C. The human hepatoma cell line HepG2 was maintained in DME medium (Invitrogen, Carlsbad, CA) supplemented with 10% FBS, 100 U/mL penicillin, and 100 g/mL streptomycin in 5% CO 2 at 37°C. Porcine RPE cells were prepared from porcine eyes obtained from a local abattoir. Each eye was dissected, and the anterior segment and vitreous and neural retina were removed. The eye cups were washed with PBS(-) (pH 7.4) and incubated with 0.05% trypsin at 37°C for 5 minutes. After the incubation, the RPE cells were collected from the eye cup and were cultured in DME/Ham F-12 medium supplemented with 10% FBS, 100 U/mL penicillin, and 100 g/mL streptomycin. Cells at passages 2 to 4 were used in the experiments.
Reverse Transcription-Polymerase Chain Reaction
Total RNA was isolated from hTERT-RPE cells (TRIzol; Invitrogen, Carlsbad, CA) and reverse transcribed into cDNA. First-strand cDNA was amplified in a buffer containing DNA polymerase (Ex Taq; Takara Bio, Ohtsu, Japan) and anti-Taq antibody (anti-Taq high; Toyobo, Osaka, Japan), with oligonucleotide primers (Table 1) . RT-PCR was performed under the following conditions: 1 cycle at 94°C for 1 minute followed by 10 cycles at 94°C for 1 minute and at 72°C for 3 minutes, 15 cycles at 94°C for 1 minute and 65°C for 2 minutes and at 72°C for 30 seconds, and 20 cycles at 94°C for 1 minute and 62°C for 2 minutes and at 72°C for 30 seconds, then finally 1 cycle at 72°C for 2 minutes. mRNA expression levels were measured by quantitative real-time PCR (Opticon 2 System; Bio-Rad, Hercules, CA). Reagent (SYBR Green I; Roche Diagnostics, Mannheim, Germany) was included in the reaction mixture, and the following touchdown protocol was applied: 1 cycle at 94°C for 1 minute and 40 cycles at 94°C for 30 seconds, then at (72 Ϫ 0.3 ϫ n)°C for 1 minute, where n is the number of cycles, and finally at 72°C for 30 seconds. mRNA amounts were normalized to the amount of GAPDH expression.
RNA Interference
Gene-silencing experiments were performed with double-strand short interfering (si) RNAs directed against arginase II (sense 5Ј-GGGGACUAAC-CUAUCGAGAAG-3Ј and antisense 5Ј-UCUCGAUAGGUUAGUCCCCCG-3Ј) and ODC (sense 5Ј-AAAAGAGACCUAAACCAGAUGAGAAAG-3Ј and antisense 5Ј-UUCUCAUCUGGUUUAGGUCUCUUUUAU-3Ј). A scrambled control siRNA (sense 5-AUCCGCGCGAUAGUACGUAUU-3Ј and antisense 5Ј-UACGUACUAUCGCGCGGAUUU-3Ј) that had no sequence homology to any known human gene was used as the control. hTERT-RPE cells were transfected with siRNA using reagent (Lipofectamine 2000; Invitrogen) according to the manufacturer's instructions.
Determination of Cytotoxicity
Cytotoxicity was evaluated morphologically using micrographs obtained with a digital camera (SPOT; Diagnostic Instruments, Sterling Heights, MI) through an inverted confocal microscope (IX70; Olympus, Tokyo, Japan). Cytotoxicity was quantitatively determined using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay, as described previously.
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Measurement of [ 14 C]Ornithine Uptake
The uptake of ornithine after treatment with 0.5 mM 5-FMO and 10 mM ornithine in hTERT-RPE cells was determined using L-[U- 14 C]ornithine (9.25 GBq/mmol; GE Healthcare, Little Chalfont, UK), as described previously.
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Griess Method
NO levels were determined as the amount of nitrite (NO 2 Ϫ ) accumulated in culture media using Griess reagent (1% sulfanilamide, 0.1% N-(1-naphthyl)ethylenediamine dihydrochloride, 5% H 3 PO 4 ). 24 Culture media were collected after the cells were treated with 5-FMO and ornithine. Protein contents in the cells were determined using an assay kit (DC Protein Assay; Bio-Rad), with bovine serum albumin as the standard.
Statistical Analysis
For single comparison between two groups, an unpaired Student's t-test was used. Data are expressed as the mean Ϯ SD of at least three separate experiments. Levels of P Ͻ 0.05 were considered to be statistically significant.
RESULTS
NO Production
It has been reported that arginine facilitates ornithine cytotoxicity in OAT-deficient hTERT-RPE cells. 15 In the present study, hTERT-RPE cells treated with arginine (10 mM) alone for 48 hours showed morphologic changes and reduced cell density ( Fig. 1) . Furthermore, morphologic changes and cell death were evident in cells treated with arginine and 0.5 mM 5-FMO, as they were in cells treated with 10 mM ornithine and 0.5 mM 5-FMO. In addition to the accumulation of ornithine caused by OAT deficiency, we speculated that arginine and its metabolites such as NO, in addition to ornithine, are involved in the cytotoxicity of RPE cells in GA.
We also examined the production of NO in hTERT-RPE cells pretreated with both 10 mM ornithine and 0.5 mM
TABLE 1. Primer Sequences Used for RT-PCR Analysis
Gene
Primer
5-FMO ( Fig. 2A ). NO production, determined by nitrite levels, was linearly increased in hTERT-RPE cells in a time-dependent manner and was significantly enhanced by ornithine in 5-FMOtreated cells after 48 hours. The amount of NO production by 5-FMO and ornithine was similar to that by 1 nM IL-6 (Supplementary Fig. S1 , http://www.iovs.org/lookup/suppl/doi:10. 1167/iovs.10-5516/-/DCSupplemental). In addition, RT-PCR analysis revealed that eNOS, but not nNOS, mRNA was expressed in hTERT-RPE cells, whereas the expression of iNOS mRNA was obviously upregulated by ornithine in 5-FMOtreated hTERT-RPE cells at 1, 6, and 24 hours after treatment (Fig. 2B) . To examine the effect of NO on the cytotoxicity of hTERT-RPE cells, we used the NO donors S-nitroso-N-acetyl-DLpenicillamine (SNAP) and S-nitrosoglutathione (GSNO). MTT colorimetric assay results showed that 1 mM SNAP and GSNO increased the cytotoxicity of hTERT-RPE cells to 30.0% and 15.9%, respectively, after 24 hours (Fig. 2C) . Thus, the cytotoxic effects induced by NO donors were evidently increased in a time-dependent manner. Furthermore, an NOS inhibitor, N G -nitro-L-arginine methyl ester (L-NAME, 0.5 mM), significantly suppressed cytotoxicity by 9.1% at 5 mM ornithine, 16.4% at 7 mM ornithine, and 17.9% at 10 mM ornithine (Fig.  2D ). These results suggest that NO produced in our in vitro GA model is involved in the cytotoxicity of hTRET-RPE cells.
Next, we determined whether NO production was also observed in freshly prepared porcine RPE cells. As shown in Figure 3 , NO production was linearly increased in the cells, and it was enhanced by the treatment with ornithine and 5-FMO. Although iNOS, eNOS, and nNOS were expressed in porcine RPE cells, the expression of iNOS mRNA was slightly increased at 48 hours after treatment with ornithine and 5-FMO.
Induction of Arginase II mRNA
Given that arginine is hydrolyzed to ornithine by arginase, we next examined the mRNA expression of arginase in hTERT-RPE cells using RT-PCR. Arginase II was exclusively expressed in hTERT-RPE cells treated with 10 mM ornithine and 0.5 mM 5-FMO for 24 hours, whereas both arginase I and arginase II were detected in a human hepatoma cell line HepG2 cells (Fig. 4A) . Quantitative real-time PCR showed that arginase II mRNA was slightly detected before treatment with ornithine and 5-FMO and then was increased from 3 to 48 hours after treatment in a time-dependent manner to 18.3-fold greater than untreated cells (Fig. 4B) . There was no effect on the expression of arginase I by treatment with 5-FMO and ornithine (data not shown). Furthermore, the expression of CAT-1 mRNA was increased from 6 to 24 hours after treatment with 5-FMO and ornithine and gradually decreased for the next 24 hours ( 
Upregulation of Arginase II mRNA by Ornithine
Ornithine alone at 5 and 10 mM significantly increased arginase II mRNA levels in hTERT-RPE cells after 24 hours (Fig. 5A) . Furthermore, the upregulation of arginase II by ornithine was markedly enhanced in cells treated with 0.5 mM 5-FMO. We also examined the involvement of ODC in arginase II mRNA expression using an ODC inhibitor, ␣-difluoromethylornithine (DFMO), and ODC siRNA because ornithine is metabolized to polyamines by ODC. DFMO at 5 mM dissolved in PBS(Ϫ) enhanced the expression of arginase II evoked by treatment with 10 mM ornithine and 0.5 mM 5-FMO for 24 hours compared with vehicle-treated cells (Fig. 5B) . The transfection of ODC siRNA (30 nM) markedly reduced the expression of ODC mRNA regardless of treatment with ornithine and 5-FMO (Fig.  5C) . However, the upregulation of arginase II mRNA induced by ornithine and 5-FMO was not decreased by ODC siRNA, and it was partially increased (Fig. 5D) . These results suggest that the increase in arginase II mRNA was mediated by ornithine, but not by ornithine metabolites, through ODC.
Upregulation of Arginase II mRNA by NO
Arginine (5 and 10 mM) also increased arginase II mRNA levels in hTERT-RPE cells after 24 hours (Fig. 5E ), whereas treatment treatment with 20 M of S-2-boronoethyl-L-cysteine (BEC), an arginase inhibitor (Fig. 5F ), suggesting that arginine itself and its metabolite NO are involved in the induction of arginase II. An NOS inhibitor, L-NAME (1 mM), partially inhibited the upregulation of arginase II mRNA expression induced by 10 mM ornithine and 0.5 mM 5-FMO (Fig. 6A ). In addition, SNAP (500 M) significantly increased the expression of arginase II mRNA by 1.8-fold greater than the control hTERT-RPE cells after 48 hours (Fig. 6B) . Similarly, the induction of CAT-1 mRNA expression, but not that of ODC, was enhanced by SNAP. These results indicate that NO regulates arginase II and CAT-1 in hTERT-RPE cells in a transcriptional manner.
Effect of Arginase II on hTERT-RPE Cell Viability
Because arginase I was found lacking in hTERT-RPE cells (Fig.  4A) , we concluded that arginase II is preferentially directed to ornithine in mitochondria. To investigate the role of arginase II in hTERT-RPE cell viability, we used arginase II siRNA and an arginase inhibitor, BEC. Transfection of arginase II siRNA (240 nM) markedly reduced the expression of arginase II mRNA regardless of treatment with 10 mM ornithine and 0.5 mM 5-FMO (Fig. 7A ). Cells transfected with the control siRNA showed shrinkage and reduced cell density after treatment with ornithine and 5-FMO, whereas cytotoxicity was enhanced by transfection of arginase II siRNA (Fig. 7B) . MTT colorimetric assays for mitochondria activity revealed a significant increase of cytotoxicity in cells transfected with arginase II siRNA (control siRNA, 41.3%; arginase II siRNA, 49.0%), whereas no effect of arginase II siRNA with regard to cytotoxicity was seen in the untreated cells. Similar results for ornithine cytotoxicity were observed in cells treated with BEC at 20 M ( Fig. 7C ; vehicle, 48.9%; BEC, 62.0%). These findings suggest that arginase II silencing leads to enhancement of ornithine cytotoxicity in hTERT-RPE cells.
Cytotoxicity of Arginase II Silencing via NO
Recently, we reported that the upregulation of CAT-1 exhibited ornithine cytotoxicity. 12 As shown in Figure 8A , the present results showed increased upregulation of CAT-1 mRNA by treatment with 10 mM ornithine and 0.5 mM 5-FMO in both control and arginase II siRNA-transfected cells to 16.5-and 13.2-fold, respectively, after 24 hours compared with the control siRNA-transfected untreated cells. There was no significant difference in [ 14 C]ornithine uptake between the control cells and those transfected with arginase II siRNAs (Fig. 8B) . These results suggest that arginase II silencing is reduces to 20% in the induction of CAT-1 mRNA, but it has no significant effect on ornithine transport in hTERT-RPE cells.
On the other hand, NO production induced by treatment with 10 mM ornithine and 0.5 mM 5-FMO was increased significantly in arginase II siRNA-transfected hTERT-RPE cells to 1.3-fold that of the control siRNA-transfected cells after 48 hours (Fig. 8C) . Similar results with regard to NO production were observed in cells treated with 10 mM arginine (Fig. 8D) . These results suggest that arginase II silencing leads to an increase of NO in hTERT-RPE cells and subsequent cell death.
DISCUSSION
In the present study, we found a novel mechanism related to the effects of arginine metabolic processes such as NOS and arginase on the cytotoxicity of OAT-deficient RPE cells. NO production was gradually increased by ornithine in OAT-deficient hTERT-RPE cells, and iNOS mRNA expression was transiently induced in the cells (Figs. 2A, 2B) . Furthermore, arginine and NO donors evoked the cytotoxicity of RPE (Figs. 1,  2C ). We also noted that the expression of arginase II mRNA was increased by ornithine and arginine in OAT-deficient hTERT-RPE cells (Figs. 4, 5) , whereas NO transcriptionally upregulated arginase II and CAT-1 (Fig. 6 ). In addition, arginase II siRNA and an arginase inhibitor enhanced ornithine cytotoxicity (Fig. 7) . Finally, arginase II siRNA enhanced NO production induced by ornithine in OAT-deficient hTERT-RPE cells (Fig. 8) .
The molecular mechanism of GA, which requires ornithine accumulation, has been described. [5] [6] [7] We previously reported that the expression of CAT-1, an ornithine transporter, was increased in our in vitro GA model, and the induction of CAT-1 was involved in ornithine cytotoxicity of RPE cells. 11, 12 On the other hand, OAT-deficient hTERT-RPE cells were severely damaged by ornithine combined with arginine, 15 whereas arginine alone induced cell death in the present study (Fig. 1) . In the present experiments, the production of NO, a metabolite of arginine, was detected in our in vitro GA model ( Fig. 2A) . In addition, iNOS induction was observed at 1 hour after treatment with ornithine and reached a maximum level after 6 hours and was decreased after 24 hours in OAT-deficient hTERT-RPE cells (Fig. 2B) . hTERT-RPE cells stably expressed eNOS, and basal NO production increased linearly. The increase of NO production by ornithine in the OAT-deficient cells was due to iNOS induction. Furthermore, the NO donors SNAP and GSNO induced cell death in hTERT-RPE cells (Fig.  2C) . Thus, it seems that in addition to ornithine accumulation, NO production in our in vitro GA model is involved in cytotoxicity.
In addition to NOS, arginine is a substrate for arginase. In the present study, we detected the upregulation of arginase II mRNA in our in vitro GA model (Fig. 4) . Arginase II upregulation contributes to several diseases, such as vasoregulatory systemic dysfunction, 25, 26 pulmonary artery hypertension, 27 diabetic-associated erectile dysfunction, 28 and atherosclerosis. 29 Previous studies have also shown that arginase II is transcriptionally regulated by lipopolysaccharide in macrophages, 30, 31 liver X receptors, which have been implicated in lipid metabolism and inflammation in macrophages, 32 interferon regulatory factor 3 (IRF3) in T lymphocytes, 33 and cAMP in Caco-2 tumor cells. 34 In the present experiments, the upregulation of arginase II in OAT-deficient hTERT-RPE cells was triggered by ornithine but not by ornithine metabolites with ODC. We found that ornithine increased arginase II expression in a dose-dependent manner (Fig. 5A) , whereas DFMO and ODC siRNA did not reduce the induction of arginase II, but rather enhanced it (Figs. 5B, 5D ). The enhancement of arginase II might have been due to the maintenance of ornithine concentration entailing ODC deficiency. We also noted that the maximal induction of CAT-1 preceded that of arginase II (Fig.  4B) . Furthermore, the addition of 5-FMO enhanced the expression of arginase II mRNA induced by ornithine (Fig, 5A) , suggesting that the accumulation of ornithine by OAT deficiency is the result of arginase II upregulation. On the other hand, the NOS inhibitor L-NAME partially inhibited the upregulation of arginase II induced by ornithine in OAT-deficient hTERT-RPE cells (Fig. 6A) , suggesting that NO takes part in the induction of arginase II in addition to ornithine. This was further supported by our findings showing that arginase II upregulation was detected in cells treated with arginine (Fig. 5E) , that the induction by arginine was unaffected by an arginase inhibitor BEC (Fig. 5F ), and the NO donor SNAP increased the level of arginase II mRNA (Fig. 6B) . Similarly, CAT-1 expression was upregulated by SNAP in hTERT-RPE cells, though CAT-1 mRNA has also been shown to be upregulated by polyamines, which are ornithine metabolites. 12 Because NO has demonstrated abilities to both upregulate and downregulate the expression of genes in mammalian cells, 35, 36 another possible mechanism of NO for cytotoxicity in hTERT-RPE cells appears to be the transcriptional regulation of arginase II and CAT-1. Ornithine transiently upregulated iNOS expression after 1 hour in OATdeficient hTERT-RPE cells (Fig. 2B) , whereas the upregulation of arginase II and CAT-1 started at 3 and 6 hours, respectively, after treatment (Fig. 4B) . The initial induction of iNOS may be involved in the deterioration associated with progressive cytotoxicity of RPE. There is no report showing the induction of arginase II or iNOS by treatment with ornithine, though the induction of CAT-1 by polyamine is involved in transcription factor c-myc. 12 Some transcription factors, such as liver X receptor, 32 IRF3, 33 and cAMP-response element binding protein (CREB), 34 have been suggested to induce arginase II based on the use of chemical inhibitors. The induction of iNOS expression is regulated by many transcription factors. cAMP enhances iNOS induction in some cell types, including rat RPE-J cells 20 ; therefore, CREB might be used as a common transcription factor for arginase II and iNOS induction.
Because arginase I is lacking in hTERT-RPE cells (Fig. 4A ) and RPE in vivo, 22 arginase II may preferentially direct ornithine to proline and glutamate production in mitochondria and polyamine synthesis in the cytosol. OAT was found to be deficient in our in vitro GA model; thus, we initially speculated that the suppression of arginase II would decrease the concentration of ornithine or polyamine in hTERT-RPE cells, resulting in the prevention of cell death. However, arginase II silencing by siRNA and the inhibitor for arginase, BEC, both aggravated cell death instead of preventing it after treatment with ornithine and 5-FMO (Fig. 7) . Although arginase II silencing had no effect on the pathophysiological processes related to ornithine cytotoxicity, such as the induction of CAT-1 mRNA and ornithine transport (Figs. 8A, 8B) , it increased NO production after treatment with ornithine and 5-FMO (Fig. 8C ). In addition, arginine induced cytotoxicity ( Fig. 1 ) and increased NO production (Fig. 8D) , suggesting that the resultant increase of arginine, a substrate of arginase, by arginase II silencing is involved in cytotoxicity. Conversely, the upregulation of arginase II may have implications for NO production by RPE cells, in addition to ornithine production. Both NOS and arginase catalyze arginine, whereas arginase may reciprocally regulate NO production by competing with NOS activity for arginine. 16, 37, 38 Overexpression of arginase I and arginase II reduces basal NO production in endothelial cells, 39 whereas arginase II upregulated by lipopolysaccharide inhibits NO production in macrophages. 31, 32 In our study, arginase II silencing by siRNA enhanced NO production induced by treatment with ornithine and 5-FMO (Fig. 8C) . Thus, the upregulation of arginase II in our in vitro GA model might have decreased NO formation and protected against subsequent cell death by NO.
We previously reported ornithine cytotoxicity, 10 transport of ornithine by CAT-1, 11, 15 and upregulation of CAT-1 expression by polyamines after ODC induction 12 in experiments with our in vitro GA model. In addition to CAT-1 and ODC, we demonstrated the induction of iNOS and arginase II by ornithine in OAT-deficient hTERT-RPE cells in the present study. NO was produced by ornithine in OAT-deficient hTERT-RPE cells, which induced the upregulation of arginase II and CAT-1, and cytotoxicity. Arginase II upregulation may protect RPE cells against cytotoxicity induced by NO rather than ornithine. Our findings suggest that NO, a metabolite of arginine, as well as ornithine is involved in the molecular mechanism of GA and may provide further evidence regarding the benefits of an arginine-restricted diet for patients with GA. In addition, regulation of NO production in RPE cells may be an effective target in a novel therapy for chorioretinal degeneration in GA.
